Disease · MONDO_0007886

uterine corpus leiomyoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. uterine corpus leiomyoma. Diseases, record MONDO_0007886. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007886

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: uterine corpus leiomyoma; Open Targets
Open Targets ID: MONDO_0007886; Open Targets
Other names: Benign uterine leiomyomas, Uterine leiomyoma, body of uterus fibroid, body of uterus leiomyoma, corpus uteri fibroid, corpus uteri leiomyoma, fibroid of body of uterus, fibroid of corpus uteri, fibroid of the body of uterus, fibroid of the corpus uteri, fibroid of the uterine body, fibroid of the uterine corpus, fibroid of uterine body, fibroid of uterine corpus, leiomyoma of body of uterus, leiomyoma of corpus uteri, leiomyoma of the body of uterus, leiomyoma of the corpus uteri, leiomyoma of the uterine body, leiomyoma of the uterine corpus, leiomyoma of uterine body, leiomyoma of uterine corpus, plexiform leiomyoma, uterine body fibroid, uterine body leiomyoma, uterine corpus fibroid, uterine corpus leiomyomata, uterine fibroid; Open Targets
Disease Ontology: DOID:13223; Disease Ontology
NCI Thesaurus: C3434; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 40 drugs, from PMDA; Open Targets

Drugs40

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RELUGOLIX	CHEMBL1800159	Small molecule	Approval	PMDA	10	9	9	Drugs and targets
TELAPRISTONE ACETATE	CHEMBL2105694	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
NORETHINDRONE ACETATE	CHEMBL1201146	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
ESTRADIOL	CHEMBL135	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
ULIPRISTAL ACETATE	CHEMBL260538	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
MIFEPRISTONE	CHEMBL1276308	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
MISOPROSTOL	CHEMBL606	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
ASOPRISNIL	CHEMBL267431	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
VILAPRISAN	CHEMBL3989936	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
ELAGOLIX	CHEMBL1208155	Small molecule	Phase 3	ClinicalTrials.gov and TTD	7	6	6	Drugs and targets

1 to 10 of 40

See all 40 drugs

Targets51

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GNRHR	Gonadotropin-releasing hormone receptor	10	Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist	Approval	https://conductscience.org/library/genes/2798	Drugs and targets
PGR	Progesterone receptor	8	Progesterone receptor agonist; Progesterone receptor antagonist; Progesterone receptor modulator	Phase 3	https://conductscience.org/library/genes/5241	Drugs and targets
AVPR1A	Vasopressin V1 receptor	2	Vasopressin V1 receptor binding agent; Vasopressin receptor agonist	Unknown	https://conductscience.org/library/genes/552	Drugs and targets
AVPR1B	Vasopressin V1 receptor	2	Vasopressin V1 receptor binding agent; Vasopressin receptor agonist	Unknown	https://conductscience.org/library/genes/553	Drugs and targets
AVPR2	Vasopressin V2 receptor	2	Vasopressin V2 receptor binding agent; Vasopressin receptor agonist	Unknown	https://conductscience.org/library/genes/554	Drugs and targets
OXTR	Oxytocin receptor	2	Oxytocin receptor agonist	Phase 3	https://conductscience.org/library/genes/5021	Drugs and targets
PTGER3	Prostaglandin E2 receptor	2	Prostaglandin E2 receptor agonist; Prostanoid EP3 receptor agonist	Phase 3	https://conductscience.org/library/genes/5733	Drugs and targets
ADRA1A	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/146	Drugs and targets

1 to 10 of 51

See all 51 targets

Trials103

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03194646	Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids	Phase 3	1,272	2021-08-26	Uterine Fibroids	VILAPRISAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01817530	Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)	Phase 2	571	2020-07-21	Heavy Uterine Bleeding, Uterine Fibroids	ELAGOLIX, ESTRADIOL, NORETHINDRONE ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03412890	LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	Phase 3	477	2024-05-09	Heavy Menstrual Bleeding, Uterine Fibroid	ESTRADIOL, NORETHINDRONE ACETATE, RELUGOLIX	Its record names the disease	ClinicalTrials.gov
NCT01629563	PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata	Phase 3	451	2019-09-04	Uterine Fibroids	ULIPRISTAL ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02925494	An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	Phase 3	433	2020-06-30	Uterine Fibroids, Heavy Menstrual Bleeding	ELAGOLIX, ESTRADIOL, NORETHINDRONE ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02654054	Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women	Phase 3	413	2020-06-29	Uterine Fibroids, Heavy Menstrual Bleeding	ELAGOLIX, ESTRADIOL, NORETHINDRONE ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03103087	LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	Phase 3	382	2022-04-20	Heavy Menstrual Bleeding, Uterine Fibroid	ESTRADIOL, NORETHINDRONE ACETATE, RELUGOLIX	Its record names the disease	ClinicalTrials.gov
NCT02691494	Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)	Phase 3	378	2020-06-30	Uterine Fibroids, Heavy Menstrual Bleeding	ELAGOLIX, ESTRADIOL, NORETHINDRONE ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02131662	Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap	Phase 2	309	2017-12-08	Leiomyoma	VILAPRISAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00740831	PGL4001 Versus GnRH-agonist in Uterine Myomas	Phase 3	301	2012-11-16	Uterine Myomas	LEUPROLIDE ACETATE, ULIPRISTAL ACETATE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 103

See all 103 trials

Comparisons in its trials22

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ulipristal Acetate (PGL4001) 5mg vs Ulipristal Acetate (PGL4001) 10mg: serious adverse events	16 of 230	12 of 221	451	NCT01629563	Trial comparisons
Relugolix 40 mg vs Leuprorelin 1.88 mg or 3.75 mg: Number of Participants With TEAE Related to Weight	0 of 138	0 of 142	280	NCT02655237	Trial comparisons
Relugolix 40 mg vs Leuprorelin 1.88 mg or 3.75 mg: Number of Participants With TEAE Related to Standard 12-Lead ECGs	0 of 138	0 of 142	280	NCT02655237	Trial comparisons
Relugolix 40 mg vs Leuprorelin 1.88 mg or 3.75 mg: Number of Participants Who Had One or More Treatment Emergent Adverse Event (TEAE)	131 of 138	139 of 142	280	NCT02655237	Trial comparisons
Relugolix 40 mg vs Leuprorelin 1.88 mg or 3.75 mg: deaths from any cause	0 of 138	0 of 142	280	NCT02655237	Trial comparisons
Relugolix 40 mg vs Leuprorelin 1.88 mg or 3.75 mg: Number of Participants With TEAE (Bone Density Decreased) Related to Bone Mineral Density	6 of 138	8 of 142	280	NCT02655237	Trial comparisons
Relugolix 40 mg vs Leuprorelin 1.88 mg or 3.75 mg: serious adverse events	0 of 138	2 of 142	280	NCT02655237	Trial comparisons
Relugolix Plus E2/NETA (Group A) vs Placebo (Group C): Sustained Amenorrhea Rate (No Or Negligible Bleeding)	63 of 125	4 of 129	254	NCT03103087	Trial comparisons
Relugolix Plus E2/NETA (Group A) vs Placebo (Group C): Number Of Responders With At Least 20 Points Decrease in UFS-QoL Bleeding And Pelvic Discomfort Scale Score	79 of 125	37 of 129	254	NCT03103087	Trial comparisons
Relugolix Plus E2/NETA (Group A) vs Placebo (Group C): Number Of Responders With At Least 20 Points Increase From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score	78 of 125	42 of 129	254	NCT03103087	Trial comparisons

1 to 10 of 22

See all 22 comparisons in its trials

Papers from its trials82

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39084498	RESULT	1	PubMed
38453041	RESULT	1	PubMed
37666383	RESULT	2	PubMed
36989026	RESULT	1	PubMed
36357960	RESULT	3	PubMed
36303616	RESULT	1	PubMed
34741454	RESULT	1	PubMed
33596357	RESULT	2	PubMed
33461754	RESULT	1	PubMed
32532486	RESULT	1	PubMed

1 to 10 of 82

See all 82 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007886

GET https://conductscience.org/api/diseases/v1/MONDO_0007886/drugs?page=2

API reference For AI assistants